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ABSTRACT
Background: Hodgkin lymphoma (HL) is the paradigm of curable disease. This 
study analyzed the overall survival (OS) of patients with HL and compared their 
survival between decades and with the expected survival of a general population.
Results: The median follow-up was 22 years. The median OS was 33 years. The 
incidence mortality rate for all causes is 2 per every 100 patients per year. The OS 
of our cohort at 10 years from diagnosis was 76% (95% CI: 72–79) and 52% at  
30 years (95% CI: 48–57). Overall SMR (1980–2013) was 2,943 (95% CI: 2,518–3,439).  
Excluding the primary tumor as the cause of death, the SMR obtained is 2,266 (95% 
CI: 1,895–2,710). The SMR for those patients diagnosed before the year 2000 was 
2,097 (95% CI: 1,732–2,539); and for those diagnosed after 2000 was 5,218 (95% 
CI: 8,655). The group of patients diagnosed after 2000 had statistically significant 
more advanced stages, were older and less responsive to treatment.
Conclusions: Despite the advances achieved, the risk of death remains higher 
than in the general population, mainly for those patients diagnosed after year 2000, 
even after almost 40 years of follow-up. This data might suggest a shift to more 
aggressive forms of disease in recent years.
Patients and methods: A total of 595 patients diagnosed with HL were included 
between January 1966 and February 2014. The standardized mortality ratio (SMR) 
was analyzed using the annual rate of mortality in the general Spanish population, 
adjusted for age, sex and time period.
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INTRODUCTION
Hodgkin lymphoma (HL) is the paradigm of curable 
disease within the field of Medical Oncology, along with 
germ cell tumors. Globally, 65950 new cases of HL are 
diagnosed each year, accounting for 0.5% of all cancer 
diagnoses [1]. It is therefore considered a rare disease. In 
Spain, this disease has an incidence rate higher than that 
of the world population (2.1 and 2.5 cases per 100,000 
persons-year in women and men, respectively, in Spain, 
compared to 0.7 and 1.1 cases worldwide) [2]. Besides, the 
current Spanish trend is that new diagnoses are increasing 
(12.5–14.7% more), according to the Spanish Network of 
Cancer Registries (REDECAN) [3].
In recent decades, due to the improvement in 
diagnostic techniques, advances in molecular biology and 
in the development of therapeutic options, the survival of 
these patients has been significantly increased [4]. This 
fact leads to the need to monitor the occurrence of late 
complications, such as the appearance of second tumors 
or cardiovascular events, with a consequent impact on the 
morbidity and mortality of these patients [5]. However, 
there is little information regarding the impact of new 
treatments regarding late toxicities, adapted to the patient’s 
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risk, with less extension in the radiotherapy field and 
shorter chemotherapy schemes.
The main objective of this study was to analyze the 
overall survival (OS) of patients with HL and to compare 
it with the expected survival in the general Spanish 
population, with a long follow-up and search for a possible 
improvement in survival in the last decades of treatment, 
and whether there has been any change in long-term 
morbidity and mortality.
RESULTS
Patient characteristics and survival analysis
Out of a total of 624 patients diagnosed with HL, 
29 patients diagnosed prior to 1975 were excluded due to a 
lack of epidemiological population data prior to that date. 
Patient characteristics are described in Table 1. 
The median follow-up was 22 years (p25-p75: 
8–30 years) for the entire cohort and 29 years (p25-p75: 
17–33 years) for disease-free alive patients.
The median OS was 33 years. The incidence 
mortality rate for all causes is 2 per every 100 patients 
per year. The OS of our cohort at 10 years was 76% 
(95% CI: 72–79), at 20 years 66% (95% CI: 62–70), at 
30 years 52% (95% CI: 48–57) and at 40 years 42% (95% 
CI: 36–49%) (Figure 1). The PFS at 10 years was 63% 
(95% CI: 58–67), at 20 years 55% (95% CI: 51–60), at 
30 years 46% (95% CI: 41–51), and at 40 years 39% 
(95% CI: 33–45%) (Figure 2). The DFS for those patients 
with a complete response at 10 years was 64% (95% CI: 
60–68), at 20 years 57% (95% CI: 52–61), at 30 years 
48%: 43–52) and at 40 years 40% (95% CI: 34–47%) 
(Figure 3)
Comparison between mortality rates by study 
group and general population
SMR was used to quantify the increase or decrease 
in mortality of the study cohort compared to the general 
Spanish population. Overall SMR, including all-cause 
death, was 2,943 (95% CI: 2,518–3,439), indicating 
that patients with HL triple on average the risk of death 
compared to the general population.
Stratifying by sex, women had a higher mortality rate 
than men, with an SMR of 4,220 (95% CI: 3,119– 5,584), 
compared to 2,590 (95% CI: 2,147–3,125), respectively 
(Figure 4). Regarding the analysis of the different age 
groups at diagnosis, those patients belonging to the 
younger age group (≤30 years) presented a significantly 
higher SMR than the other groups, with an SMR of 9,653 
(95% CI: 7,555–12,333). In patients between 31 and 59 
years of age, SMR was 2,560 (95% CI: 1,996–3,283) 
and in the population over 60 years of age it was 1,400 
(95% CI: 0.991–1.980), finding no differences in mortality 
compared to the general population.
Regarding the analysis according to the year to the 
diagnosis, for those patients with HL diagnosed before the 
year 2000, the SMR was 2,698 (95% CI: 2,282–3,190); 
while for patients diagnosed after the year 2000 it was 
7,195 (95% CI: 4,691–11,035).
Excluding the primary tumor as the cause of death, 
the SMR obtained is 2,266 (95% CI: 1,895–2,710). If the 
cohort is divided according to the year of diagnosis of HL, 
the SMR for those diagnosed before the year 2000 was 
2,097 (95% CI: 1,732–2,539); and for those diagnosed 
after 2000 was 5,218 (95% CI: 3,146–8,655).
Adjusted analysis
A multivariable Cox regression was performed to 
jointly assess the association of gender, age at diagnosis, 
and year of diagnosis (before and after the year 2000) 
with all-cause mortality in our cohort. Results are shown 
in Table 2.
The variables associated with all-cause mortality 
were sex (in males, HR = 1.33, 95% CI 1.03–1.73, 
p = 0.030) and being over 60 years old (HR with respect to 
under 30 years = 4.38; % 2.98–6.43, p < 0.001).
The characteristics of the patients were analyzed 
according to the year of diagnosis in order to find an 
explanation for the SMR of the patients diagnosed after the 
year 2000, along with a worse prognosis observed within 
our cohort. The group of patients diagnosed after 2000 
(n = 96) had more advanced stages (92% presented stages 
II + III + IV vs 80% in the group < 2000, p = 0.010), were 
older (17% ≥ 60 (p < 0.001) and were less responsive to 
treatment (no complete response 20% vs 5% in the <2000 
group, p < 0.001) (Table 3).
DISCUSSION
In Oncology, HL is usually presented as an example 
of curable disease due to its high number of DFS [6]. 
However, long-term survival studies have described 
that patients with HL do not have the same mortality 
compared to the general population, adjusted for age and 
sex [7]. In routine clinical practice, patient follow-up is 
focused on the early detection of complications such as 
the development of second malignancies, cardiac toxicities 
or other toxicities associated to treatment, which are 
commonly the cause of death [8].
In 1999, Provencio et al. [9] demonstrated an 
increased risk of mortality in patients with HL compared 
to the general Spanish population, 20 years after diagnosis.
In this study, we reported that even after almost 
40 years from diagnosis of HL, patients triple the 
risk of death from all causes, compared to the general 
population. When studying the different causes of death, 
only 22.76% of them were due to the lymphoma itself. 
Therefore, the excess death observed in these patients is 
mainly due to other causes, primely second tumors, fatal 
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cardiac events or other causes not related to the primary 
tumor). It is postulated that the risk of developing second 
malignancies is mainly due to complications derived from 
radiotherapeutic treatment used in HL, age, smoking 
history, and recently, it has been associated with a genetic 
predisposition [10, 11].
The risk of death was significantly higher in women 
than in men. However, in the internal analysis of our 
cohort, it was the men who had a higher risk of mortality 
by any cause, mainly due to presenting more advanced 
disease subtypes (lymphocyte depletion) at the time of 
diagnosis. Also of note, the great mortality of patients 
under 30 years of age (eleven-fold; SMR of 11.14), which 
could be justified by the fact that in the general population 
of the same age, the risk of death is very low, so a fatal 
event in our cohort would have a greater impact on the 
difference between observed and expected events.
In addition, and despite the advances achieved in 
the treatment of HL in the last decade, the risk of death 
was even greater in patients diagnosed after 2000. To 
Table 1: Patient demographics
Characteristics Valid N N (%)
Sex
Male
Female
594
366 (61.62)
228 (38.38)
Age at diagnosis (years)
≤30 years
31–59 years
≥60 years
590
308 (52.20)
238 (40.34)
44 (7.46)
Year of diagnosis
<2000
≥2000
591
495 (83.76)
96 (16.24)
Ann Arbor stage
I
II
III
IV
585
103 (17.61)
269 (45.98)
137 (23.41)
76 (12.99)
Hodgkin lymphoma subtypes
Nodular sclerosis (NS)
Mixed cellularity (MC)
Lymphocyte-rich (LR)
Lymphocyte depleted (LD)
Non-Specified (NS)
589
271 (46.01)
196 (33.28)
41 (6.96)
51 (8.66)
30 (5.09)
Response to treatment
Complete
Non complete
573
532 (92.84)
41 (7.16)
Relapse
Yes
No
558
174 (31.18)
384 (68.82)
Secondary tumor development
Yes
No
516
106 (20.54)
410 (79.46)
Exitus
Yes
No
591
259 (43.82)
332 (56.18)
Cause of death
Primary tumor
Secondary tumor
Other causes
246
56 (22.76)
56 (22.76)
134 (54.47)
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Figure 1: Kaplan-Meier curve for overall survival (OS) of the cohort. 
Figure 2: Kaplan-Meier curve for progression-free survival (PFS) of our cohort.
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understand the differences in mortality in relation to the 
time of diagnosis (before and after 2000), we compared 
both subgroups in our cohort. Patients diagnosed after 
the year 2000 had a worse prognosis, since there was a 
higher proportion of patients with advanced age (16.67% 
diagnosed after 2000 vs 5.67% diagnosed before 2000), 
and additionally had lower rates of complete response to 
initial treatment (20.25% vs 5.07%, respectively), both 
with statistical significance.
Therefore, we can conclude that in the Spanish 
population, HL currently presents a tendency towards 
more aggressive forms, with older age patients and a 
Figure 3: Kaplan-Meier curve for disease-free survival (DFS) of those patients with a complete response after first line 
treatments.
Figure 4: Forest plot of standardized mortality ratios (SMR), global and by subgroups. The forest plot was generated 
through “Distiller SR Forest Plot Generator from Evidence Partners”.
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lower rate of complete response to first line treatments. 
There may be a bias regarding the transfer of complex 
patients to third-level hospitals such as ours and this may 
not represent the real situation of the global and current 
change in this lymphoma. In all, there may be an evident 
improvement in the average life expectancy in the Western 
population in the last decades and perhaps this could 
explain the differences in the risk of death. This is verified 
with a similar rate of OS at 20 years compared to that of 
other recently published series, which is around 65% [4].
The findings observed in this study may be of great 
relevance in the study of this disease, specially considering 
the inclusion of the large number of patients and the long 
follow-up. In addition, it was performed in a third-level 
hospital setting, a reference institution in HL, where most 
clinical records are computerized, which implies a reliable 
record of the patients’ medical history. 
The interest of making future updates analyzing the 
hypotheses of this work is raised, since the development of 
new drugs, fundamentally based on anti-PD1 antibodies, 
such as nivolumab, has showed high response rates in 
adults with relapsed or refractory classical LH [12], which 
is expected to lead to a change in routine clinical practice.
Finally, this study is unique in the sense of analyzing 
the mortality of the patients comparing it to the Spanish 
population 40 years after diagnosis. Long-term follow-up 
Table 2: Multivariable Cox regression for all-cause mortality
Variables HR (CI 95%) p
Sex (male) 1.335 (1.028– 1.732) 0.030
Age at diagnosis   
≤30 years Ref. cat. ---
31–59 years 1.224 (0.938–1.596) 0.136
≥60 years 4.380 (2.983–6.430) <0.001
Year of diagnosis (≥ 2000) 1.225 (0.794–1.889) 0.359
HR: Hazard Ratio; CI: Confidence Interval.
Table 3: Patient characteristics according to the year of diagnosis (< 2000 vs ≥ 2000)
Characteristic
<2000 ≥ 2000
p
N (%) N (%)
Sex
Male
Female
307 (62.02)
188 (37.98)
57 (59.38)
39 (40.63)
0.626
Ann Arbor stage
I
II
III
IV
96 (19.39)
223 (45.05)
113 (22.83)
63 (12.73)
7 (7.95)
45 (51.14)
23 (26.14)
13 (14.77)
0.081
Age at diagnosis (years)
≤30 
31–59 
≥ 60 
267 (54.05)
199 (40.28)
28 (5.67)
41 (42.71)
39 (40.63)
16 (16.67)
0.001
Response to treatment
Complete
Non complete
468 (94.93)
25 (5.07)
63 (79.75)
16 (20.25)
0.000
Exitus
Yes
No
232 (47.15)
260 (52.85)
26 (27.08)
70 (72.92)
0.000
Cause of death
Primary tumor
Secondary tumor
Other causes
48 (21.62)
55 (24.67)
119 (53.60)
8 (34.78)
1 (4.35)
14 (60.87)
0.061
Oncotarget11644www.impactjournals.com/oncotarget
of patients with HL may therefore focus on identifying late 
complications that constitute the leading cause of death in 
these patients.
MATERIALS AND METHODS
Patients
This study was performed at the Medical Oncology 
Department, at Puerta de Hierro University Hospital 
(Madrid, Spain). A total of 595 patients diagnosed with 
HL were included at our institution between January 1966 
and February 2014. An anatomopathological confirmation 
of HL by a hematopathologist was considered mandatory 
for the inclusion of patients in the study.
The following variables were collected from 
the clinical records according to the standard hospital 
protocol: demographic data from each patient, clinical and 
pathological features, prognostic factors and treatments 
received type of response and survival, as well as the 
detection of specific causes of death.
All patients had to undergo an adequate extension 
study prior to initiation of treatment and during follow-
up. In all cases, the stage was determined according to the 
Ann Arbor classification [13], later modified in 1988 at the 
Cotswolds meeting [14].
The following chemotherapy regimens were used: 
MOPP (clomiphene hydrochloride, vincristine sulfate, 
procarbazine hydrochloride and prednisone), ABVD 
(adriamycin, bleomycin, vinblastine and dacarbazine), 
a hybrid regimen of both, or other schemes in a small 
number of patients. Radiation therapy was performed 
following Kaplan’s field recommendations [15].
Information on the progression of disease or 
relapse, re-treatment, and death, as well as its causes, was 
verified through the analysis of medical health records, 
death certificates, or National Institute of Statistics (INE) 
records. The cause of death associated with HL included 
progression of the disease independently of other causes 
of death. Non-HL related deaths were included in 
those causes that occurred independent of lymphoma, 
secondary to the toxicities of chemotherapy treatments and 
development of secondary malignancies.
The study was reviewed and approved by the Ethics 
and Clinical Research Committee of Puerta de Hierro 
University Hospital.
Statistical methodology
Standardized mortality ratio analysis
Data from the Spanish general population were 
provided by the National Center for Epidemiology and 
registered by the INE from 1980 to 2013. Therefore, 
patients diagnosed from January 1980 were selected for 
this analysis. Patients with follow-up after December 
31st 2013 were censored at this date. The standardized 
mortality ratio (SMR) is the ratio of the number of 
observed deaths (O) in our cohort versus expected (E) 
in the general Spanish population, adjusted for age, sex 
and time period. Both SMR and 95% confidence intervals 
(CI) were estimated on the hypothesis basis of the Poisson 
distribution for deaths observed in the follow-up period 
[16, 17]. Results were obtained for the entire cohort, 
segmented by gender, age groups at diagnosis (≤30, 
31–59, and ≥60 years), and year of diagnosis (<2000 and 
≥2000).
Survival analysis of the entire cohort
All patients diagnosed with HL between 1966 and 
2014 were included in this analysis. OS was defined 
as the time from diagnosis to the death of the patient; 
progression-free survival (PFS) was defined as the time 
from the end of treatment to relapse or death of the patient 
by any cause; and disease-free survival (DFS) as the time 
interval from first line treatment and a complete response, 
to relapse or death. If no events occured, observations 
were censored at the time of the last revision. The crude 
probability of the event was estimated using the Kaplan-
Meier method, and the differences between the patient 
groups were assessed using the log-rank test.
A multivariate model of Cox proportional hazards 
was estimated, including sex, age at diagnosis (including 
three categories: ≤30 years, 31–59 years and ≥60 years), 
and diagnostic period (before and after 2000) to establish 
their association together in OS. The assumption of 
proportional hazards was assessed using Schoenfeld’s 
residues [18].
All statistical tests were two-tailed, and a p value 
<0.05 was considered statistically significant. All analyses 
were performed using Stata v14.2 (StataCorp, 2015. 
CollegeStation, TX: StataCorp LP).
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